Evaluation of the effect of vitamin E therapy on children with acute kidney injury
Phase 3
Recruiting
- Conditions
- Acute kidney injury.Acute kidney failure, unspecifiedN17.9
- Registration Number
- IRCT20231119060103N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
1. People with acute kidney injury between the ages of 1 and 13 admitted to Amirkabir Hospital
2. Have the necessary cooperation in following up the treatment
3. Completing the informed consent form.
Exclusion Criteria
People who do not want to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The assessment of acute kidney injury is done by measuring the serum creatinine level. Timepoint: Measurement of serum creatinine level at the beginning of the study, 48 hours later and at the time of discharge. Method of measurement: blood sample.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does vitamin E modulate in pediatric acute kidney injury (AKI) phase III trials?
How does vitamin E therapy compare to standard-of-care interventions like fluid resuscitation in pediatric AKI outcomes?
Which biomarkers correlate with vitamin E efficacy in children with N17.9 unspecified acute kidney failure?
What are the safety profiles and adverse event management strategies for high-dose vitamin E in pediatric AKI phase III studies?
Are there synergistic effects of combining vitamin E with NAC or vitamin C in treating pediatric acute kidney injury phase III trials?